Firms Reach Cancer Drug Agreement
- Share via
Times Staff and Wire Reports
Aphton Corp. said Rhone-Poulenc’s vaccines unit has agreed to pay it up to $10 million for the right to sell its experimental cancer drug, Gastrimmune. Under the agreement, Woodland Hills-based Aphton will be responsible for the development and clinical studies of the drug, which is being developed to treat patients with stomach, liver and pancreatic cancers. Pasteur Merieux, a unit of France’s Rhone-Poulenc, will sell the drug in the United States, Canada, Europe and Mexico.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
